34.19
-0.21(-0.61%)
Currency In USD
| Previous Close | 34.4 |
| Open | 34.11 |
| Day High | 34.78 |
| Day Low | 33.9 |
| 52-Week High | 56.38 |
| 52-Week Low | 25.81 |
| Volume | 1.18M |
| Average Volume | 1.68M |
| Market Cap | 3.29B |
| PE | -6.24 |
| EPS | -5.48 |
| Moving Average 50 Days | 30.3 |
| Moving Average 200 Days | 35.47 |
| Change | -0.21 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $392.9 as of October 21, 2025 at a share price of $34.19. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $383.6 as of October 21, 2025 at a share price of $34.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
GlobeNewswire Inc.
Sep 30, 2025 8:05 PM GMT
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
GlobeNewswire Inc.
Sep 08, 2025 8:05 PM GMT
At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase 3 results are further supported by early data from
Ultragenyx to Participate at Investor Conferences in September
GlobeNewswire Inc.
Aug 29, 2025 8:30 PM GMT
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today